Aloka to buy Ecotron Holding
Ultrasound vendor Aloka of Tokyo last month agreed to purchase its European distributor, Ecotron Holding of Zug, Switzerland. The deal, valued at about $3.5 million and subject to Ecotron shareholder approval, will create a sales, marketing, and customer
Ultrasound vendor Aloka of Tokyo last month agreed to purchase its European distributor, Ecotron Holding of Zug, Switzerland. The deal, valued at about $3.5 million and subject to Ecotron shareholder approval, will create a sales, marketing, and customer support operation called Aloka Holding (Europe). The firms hoped to complete the merger last month.
Aloka's purchase of Ecotron covers Ecotron's sales and service assets, including divisions in France, Italy, and Spain. All 70 Ecotron employees will be absorbed into the new firm, and its distributor network across Eastern Europe will be restructured. Roberto Bucciarelli, president and CEO of Ecotron, will become president of Aloka Holding (Europe). With the acquisition, Aloka will increase its access to the European market, according to Masayuki Kai, Aloka president. Aloka posts worldwide revenues of about $350 million.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
